Expression and clinical significance of serum miR-27b-3p and miR-342-3p in patients with type 2 diabetic nephropathy

doi:10.11958/20220434

Abstract

Abstract:

Objective To investigate the serum expression characteristics of miR-27b-3p and miR-342-3p in type 2 diabetic nephropathy (DN) patients and the diagnostic value for DN. Methods A total of 157 patients with DN were selected and divided into the normal albuminuria group (NA group, n=49), the microalbuminuria group (MA group, n=41) and the macroalbuminuria group (DN group, n=67) according to the ratio of albumin to creatinine (UACR) of urine specimens. Clinical data and the expression of serum miR-27b-3p and miR-342-3p, renal function and urinary fibrosis indicators were detected by real-time quantitative polymerase chain reaction. Blood urea nitrogen (BUN) and blood creatinine (Scr), were detected by automatic biochemical analyzer. Urine type Ⅳ collagen (Ⅳ-C), laminin (LN) and type Ⅲprocollagen peptide (PCⅢ) were detected by double-antibody sandwich enzyme-linked immunosorbent assay. The factors influencing the pathogenesis of DN and the diagnostic value of miR-27b-3p and miR-342-3p for DN were analyzed. Results Compared with the NA group, the levels of HbA1c, UACR, urinary Ⅳ-C, urinary LN and urinary PCⅢ were increased, while the expresson levels of miR-27b-3p and miR-342-3p were decreased in the DN group and the MA group (P<0.05). Levels of BUN and Scr were increased in the DN group (P<0.05), and eGFR level decreased (P<0.05). The higher level of urinary PCⅢ was a risk factor for DN, while the higher levels of miR-27b-3p, miR-342-3p and eGFR were protective factors of DN (P<0.05). The expressions levels of miR-27b-3p and miR-342-3p were positively correlated with eGFR (r = 0.647, 0.661, P<0.05) and negatively correlated with urinary PCⅢ (r=-0.739, P<0.05). The area under the curve for diagnosing DN by combining eGFR, urinary PCⅢ, miR-27b-3p and miR-342-3p was higher than that of eGFR, urinary PCⅢ, miR-27b-3p, miR-342-3p alone (Z=5.631, 5.794, 6.715, 4.577, P<0.05). Conclusion The decreased expressions of serum miR-27b-3p and miR-342-3p are associated with decreased renal function and DN occurrence in patients with type 2 diabetes, which can be used as biological indicators for the auxiliary diagnosis of DN.

Key words: diabetic nephropathy, gene expression regulation, diagnosis, differential, miR-27b-3p, miR-342-3p, renal fibrosis

CLC Number:

R587.1

Figures/Tables 7

References 23

[1]	PENG F, GONG W, LI S, et al. circRNA_010383 acts as a sponge for mir-135a,and its downregulated expression contributes to renal fibrosis in diabetic nephropathy[J]. Diabetes, 2021, 70(2):603-615. doi: 10.2337/db20-0203.
[2]	LU B, GONG W, YANG Z, et al. An evaluation of the diabetic kidney disease definition in Chinese patients diagnosed with type 2 diabetes mellitus[J]. J Int Med Res, 2009, 37(5):14931500. doi: 10.1177/147323000903700526.
[3]	许嵘, 钟一红, 陈波, 等. 上海市郊区2型糖尿病患者肾脏疾病及其危险因素研究[J]. 中华内科杂志, 2012, 5l(1):18-23.
	XU R, ZHONG Y H, CHEN B, et al. The prevalence and risk factors of kidney disease in type 2 diabetic patients in rural Shanghai[J]. Chin J Intern Med, 2012, 5l(1):18-23. doi: 10.3760/cma.j.issn.0578-1426.2012.01.005.
[4]	ZHANG L, LONG J, JIANG W, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016, 375(9):905-906. doi: 10.1056/NEJMc1602469.
[5]	张俊清, 苏白海, 张捷, 等. 糖尿病肾病早期预测与诊断专家共识[J]. 中华内科杂志, 2021, 60(6):522-532.
	ZHANG J Q, SU B H, ZHANG J, et al. Expert consensus on early prediction and diagnosis of diabetic nephropathy[J]. Chin J Intern Med, 2021, 60(6):522-532. doi: 10.3760/cma.j.cn112138-20200603-00550.
[6]	YANG M, WANG X, HAN Y, et al. Targeting the NLRP3 Inflammasome in Diabetic Nephropathy[J]. Curr Med Chem, 2021, 28(42):8810-8824. doi: 10.2174/0929867328666210705153109.
[7]	JIANG Z H, TANG Y Z, SONG H N, et al. miRNA-342 suppresses renal interstitial fibrosis in diabetic nephropathy by targeting SOX6[J]. Int J Mol Med, 2020, 45(1):45-52. doi: 10.3892/ijmm.2019.4388.
[8]	LV X, LI J, HU Y, et al. Overexpression of mir-27b-3p targeting wnt3a regulates the signaling pathway of wnt/β-catenin and attenuates atrial fibrosis in rats with atrial fibrillation[J]. Oxid Med Cell Longev, 2019, 17(4):5703764. doi: 10.1155/2019/5703764.
[9]	ASSMANN T S, RECAMONDE-MENDOZA M, DE SOUZA B M, et al. MicroRNAs and diabetic kidney disease:Systematic review and bioinformatic analysis[J]. Mol Cell Endocrinol, 2018, 5(12):90-102. doi: 10.1016/j.mce.2018.06.005.
[10]	郭凯锋, 寇静鑫, 陆俊茜, 等. 2型糖尿病肾病患者尿中smad3蛋白的水平变化和意义[J]. 中华医学杂志, 2013, 93(14):1067-1071.
	GUO K F, KOU J X, LU J Q, et al. Change and significance of urinary smad3 in type 2 diabetic nephropathy[J]. Natl Med J China, 2013, 93(14):1067-1071. doi: 10.3760/cma.j.issn.0376-2491.2013.14.008.
[11]	刘旭辉, 王韧, 张献玲, 等. 血清miR-146a作为脓毒症诊断标记物的研究[J]. 实用医学杂志, 2017, 33(7):1103-1105.
	LIU X H, WANG R, ZHANG X L, et al. Serum miR-146a as potential biomarker for sepsis[J]. Journal of Practical Medicine, 2017, 33(7):1103-1105. doi: 10.3969/j.issn.1006-5725.2017.07.022.
[12]	MA Z, LI L, LIVINGSTON M J, et al. p53/microRNA-214/ULK1 axis impairs renal tubular autophagy in diabetic kidney disease[J]. J Clin Invest, 2020, 130(9):5011-5026. doi: 10.1172/JCI135536.
[13]	ZENG X, HUANG C, SENAVIRATHNA L, et al. miR-27b inhibits fibroblast activation via targeting TGFβ signaling pathway[J]. BMC Cell Biol, 2017, 18(1):9. doi: 10.1186/s12860-016-0123-7.
[14]	FU Q, LU Z, FU X, et al. MicroRNA 27b promotes cardiac fibrosis by targeting the FBW7/Snail pathway[J]. Aging(Albany NY), 2019, 11(24):11865-11879. doi: 10.18632/aging.102465.
[15]	LI D, ZHANG J, LIU Z, et al. Human umbilical cord mesenchymal stem cell-derived exosomal miR-27b attenuates subretinal fibrosis via suppressing epithelial-mesenchymal transition by targeting HOXC6[J]. Stem Cell Res Ther, 2021, 12(1):24. doi: 10.1186/s13287-020-02064-0.
[16]	BAI L, LIN Y, XIE J, et al. MiR-27b-3p inhibits the progression of renal fibrosis via suppressing STAT1[J]. Hum Cell, 2021, 34(2):383-393. doi: 10.1007/s13577-020-00474-z.
[17]	ZHANG M Y, CALIN G A, YUEN K S, et al. Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy[J]. Clin Epigenetics, 2020, 12(1):150. doi: 10.1186/s13148-020-00926-1.
[18]	YAN X C, CAO J, LIANG L, et al. miR-342-5p is a notch downstream molecule and regulates multiple angiogenic pathways including notch,vascular endothelial growth factor and transforming growth factor β signaling[J]. J Am Heart Assoc, 2016, 5(2):e003042. doi: 10.1161/JAHA.115.003042.
[19]	QU Y, LIU D, JIA H, et al. Circular RNA rno_circ_0004002 regulates cell proliferation,apoptosis,and epithelial-mesenchymal transition through targeting miR-342-5p and Wnt3a in anorectal malformations[J]. J Cell Biochem, 2019, 120(9):15483-15493. doi: 10.1002/jcb.28814.
[20]	ISAKA Y. Targeting TGF-β signaling in kidney fibrosis[J]. Int J Mol Sci, 2018, 19(9):2532. doi: 10.3390/ijms19092532.
[21]	ZHOU J, CHENG H, WANG Z, et al. Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF-α-Smurf1-Akt-mTOR-P70S6K pathway[J]. J Cell Mol Med, 2019, 23(8):5390-5402. doi: 10.1111/jcmm.14420.
[22]	TANG S, WANG Y, XIE G, et al. Regulation of Ptch1 by miR-342-5p and FoxO3 induced autophagy involved in renal fibrosis[J]. Front Bioeng Biotechnol, 2020, 8:583318. doi: 10.3389/fbioe.2020.583318.
[23]	JIANG Z H, TANG Y Z, SONG H N, et al. miRNA‑342 suppresses renal interstitial fibrosis in diabetic nephropathy by targeting SOX6[J]. Int J Mol Med, 2020, 45(1):45-52. doi: 10.3892/ijmm.2019.4388.

组别	n	年龄（岁）	性别（男/女）	BMI（kg/m²）
DN组	67	63.79±5.91	41/26	24.19±1.02
MA组	41	63.65±5.19	24/17	24.24±1.51
NA组	49	63.42±5.01	29/20	24.42±1.36
F或χ²		0.077	0.089	1.769

组别	n	年龄（岁）	性别（男/女）	BMI（kg/m²）
DN组	67	63.79±5.91	41/26	24.19±1.02
MA组	41	63.65±5.19	24/17	24.24±1.51
NA组	49	63.42±5.01	29/20	24.42±1.36
F或χ²		0.077	0.089	1.769

组别	n		吸烟史		高血压		高脂血症	冠心病		脑梗死		2型糖尿病病程（a）		2型糖尿病家族史
NA组	49		9（18.37）		21（61.22）		8（16.33）	10（20.41）		8（16.33）		6.12±1.54		21（42.86）
MA组	41		6（14.63）		20（58.54）		7（17.07）	9（21.95）		6（14.63）		9.24±3.08^a		17（41.46）
DN组	67		12（17.91）		47（70.15）^ab		14（20.89）	15（22.39）		12（17.91）		12.35±3.26^ab		32（47.76）
χ²或F			0.260		9.748^＊＊		0.464	0.068		0.200		93.869^＊＊		0.494
组别		合并视网膜病变		合并非酒精性脂肪肝		收缩压（mmHg）			舒张压（mmHg）		降糖治疗
组别		合并视网膜病变		合并非酒精性脂肪肝		收缩压（mmHg）			舒张压（mmHg）		口服降糖药物		胰岛素皮下注射		联合用药
NA组		3（6.12）		2（4.08）		125.35±10.35			88.95±9.02		16（32.65）		19（38.78）		14（28.57）
MA组		2（4.88）		1（2.44）		129.42±12.62^a			89.05±8.03		13（31.71）		16（39.02）		12（29.27）
DN组		18（26.87）^ab		13（19.40）^ab		135.26±15.0^ab			89.35±9.15		22（32.84）		30（44.78）		15（22.39）
χ²或F		13.977^＊＊		10.902^＊＊		3.749^＊＊			0.180		0.958

组别	n		吸烟史		高血压		高脂血症	冠心病		脑梗死		2型糖尿病病程（a）		2型糖尿病家族史
NA组	49		9（18.37）		21（61.22）		8（16.33）	10（20.41）		8（16.33）		6.12±1.54		21（42.86）
MA组	41		6（14.63）		20（58.54）		7（17.07）	9（21.95）		6（14.63）		9.24±3.08^a		17（41.46）
DN组	67		12（17.91）		47（70.15）^ab		14（20.89）	15（22.39）		12（17.91）		12.35±3.26^ab		32（47.76）
χ²或F			0.260		9.748^＊＊		0.464	0.068		0.200		93.869^＊＊		0.494
组别		合并视网膜病变		合并非酒精性脂肪肝		收缩压（mmHg）			舒张压（mmHg）		降糖治疗
组别		合并视网膜病变		合并非酒精性脂肪肝		收缩压（mmHg）			舒张压（mmHg）		口服降糖药物		胰岛素皮下注射		联合用药
NA组		3（6.12）		2（4.08）		125.35±10.35			88.95±9.02		16（32.65）		19（38.78）		14（28.57）
MA组		2（4.88）		1（2.44）		129.42±12.62^a			89.05±8.03		13（31.71）		16（39.02）		12（29.27）
DN组		18（26.87）^ab		13（19.40）^ab		135.26±15.0^ab			89.35±9.15		22（32.84）		30（44.78）		15（22.39）
χ²或F		13.977^＊＊		10.902^＊＊		3.749^＊＊			0.180		0.958

组别	n		TC （mmol/L）	TG （mmol/L）		LDL-C （mmol/L）		FPG （mmol/L）	FINS （U/mL）		HbA1c （%）		HOMA-IR	BUN （mmol/L）		Scr （μmol/L）
NA组	49		5.19±1.42	1.75±0.20		3.57±0.55		7.90±1.30	8.79±1.83		5.02±1.21		3.08±0.59	5.65±1.35		84.98±16.97
MA组	41		5.21±1.53	1.76±0.21		3.59±0.51		7.93±1.31	8.82±1.93		6.12±1.34^a		3.11±0.97	6.12±1.09		85.35±16.53
DN组	67		5.28±1.55	1.80±0.25		3.62±0.65		8.42±1.35	9.05±2.33		8.85±1.79^ab		3.39±1.08	35.26±6.32^ab		186.43±21.52^ab
F			0.276	0.537		0.317		2.765	1.805		77.594^＊＊		2.861	1 044.950^＊＊		555.002^＊＊
组别		UACR （mg/g）			eGFR [mL/（min·1.73m²）]		Ⅳ-C （μg/L）			LN （μg/L）		PCⅢ （μg/L）			miR-27b-3p （2^-ΔΔCt）		miR-342-3p （2^-ΔΔCt）
NA组		16.35±3.53			113.05±13.42		72.02±12.72			64.95±13.08		44.02±10.27			3.10±0.69		2.81±0.52
MA组		103.47±26.23^a			112.32±13.26		80.12±15.32^a			71.50±16.09^a		49.53±11.02^a			2.29±0.55^a		2.01±0.34
DN组		369.02±41.42^ab			82.35±6.43^ab		201.32±30.07^ab			136.26±28.65^ab		163.26±21.18^ab			1.02±0.35^ab		0.95±0.28^ab
F		839.418^＊＊			145.616^＊＊		707.673^＊＊			149.726^＊＊		921.650^＊＊			166.444^＊＊		249.438^＊＊